DISEASE AREA STRATEGY
Which indications offer the best commercial opportunity, and how should you prioritize them?
Before you can commit resources to a new indication, you need the evidence that your asset can win. Our framework provides insight into the where the best opportunities exist and how to prioritize them.
Disease Area Scan
Our “Disease Area Scan” tools compare key criteria across candidate indications, agnostic of new drug profiles. We begin by characterizing each population’s unmet medical need, size, and competitive intensity.
After identifying the indications that appear attractive from this assessment, we use heat maps to convey what levels of improvement in efficacy and safety will correspond to certain levels of clinical innovation and patient-share potential. These heat maps provide a useful way to guide the TPP building process.
Indication Prioritization
When a new drug is believed to have potential across multiple patient segments, our “Indication Prioritization” tools help clients identify in which populations/indications the asset has the greatest commercial outlook. Clients use these tools to determine which of those indications they should focus on for initial approval.
We provide a variety of comparative views that characterize the asset across the populations by level of unmet medical need, clinical improvement vs. the standard of care (providing insight into patient share outlook), the population size, and competitive intensity.
Oncology TPP Predictor
Equinox Group has developed a proprietary oncology-focused endpoints database, spanning over 30,000 drug regimens. It has the analytical power to project likely OS outcomes for a given TPP with known PFS, based on drug characteristics such as tumor type and mechanism.
